MELT: Modulation of PSMA Expression for Lutetium Therapy
MELT: Modulation of PSMA Expression for Lutetium Therapy
批准号:
10428614
负责人:
Felix Yi-Chung Feng
金额:
$63.82万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-07-01 至 2026-06-30
关键词:
AftercareAnimal ModelBiological MarkersBiopsyBloodCRISPR screenCell Culture TechniquesCell LineCell surfaceClinicalClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsComputational BiologyData SetDepositionDevelopmentDiseaseDoseFOLH1 geneGene ExpressionGenesGenomeGenomicsHeterogeneityImageInterventionKnowledgeLesionLutetiumMeasuresMediatingModelingMolecularNeoplasm Circulating CellsOligonucleotide MicroarraysPSA levelPathway AnalysisPathway interactionsPatientsPharmacologyPhase III Clinical TrialsPositron-Emission TomographyPublishingRadiationRadiation ToleranceRadioisotopesRandomizedSamplingSerologySystemTestingTherapeuticTherapeutic AgentsTimeTissuesToxic effectTreatment EfficacyWorkbasecancer cellcastration resistant prostate cancerdiagnostic valuedosimetryeffective therapygenomic biomarkergenomic dataimaging biomarkerimprovedneoplastic cellnovelnovel therapeuticspatient derived xenograft modelpatient populationphase III trialpredicting responseprospectiveprostate cancer cellradiation responseradioligandradiological imagingreceptorresponsesingle photon emission computed tomographytargeted treatmenttranscriptometranscriptomicstreatment responsetumoruptake
中文摘要
项目摘要
英文摘要
Project Abstract
Castrate resistant prostate cancer is a uniformly lethal disease and, although there have been a number of
new therapeutic agents approved, there is still a large need for more effective treatments in this patient
population. In this proposal, we will study a radioligand therapy (RLT) that targets the prostate specific
membrane antigen (PSMA), a molecule that is expressed on the majority of prostate cancer cells. In multiple
small studies, PSMA RLT has shown to have remarkable efficacy in heavily pretreated patients, with over 40%
of patients having decreased PSA of over 50%. PSMA RLT relies on two basic premises: targeting the
radiation to PSMA and the radiosensitivity of the tissue to the deposited radiation. First, we will understand
how PSMA expression is regulated, allowing us to pharmacologically target cancer cells to increase their
PSMA expression. Second, we will understand whether tumors respond because of intrinsic sensitivity to
radiation or high doses of deposited radiation. This knowledge will be critical to determine if patients need
higher expression of PSMA or increased tumor cell sensitivity in order to improve the response to this therapy.
We will test treatments capable of increasing the sensitivity of tumors to radiation as well as potential therapies
that can increase expression of PSMA. This work will be used to inform the development of a clinical trial that
will involve PSMA RLT and a co-administered therapy to increase its already promising efficacy.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
肽受体放射性核素治疗中治疗后成像的影响。
DOI:
10.2967/jnumed.123.266614
发表时间:
2024
期刊:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子:
--
作者:
[Yadav,Surekha, Lawhn-Heath,Courtney, Paciorek,Alan, Lindsay,Sheila, Mirro,Rebecca, Bergsland,EmilyK, Hope,ThomasA]
通讯作者:
Hope,ThomasA
DOI:
10.1088/1361-6560/abd3ef
发表时间:
2021-01-29
期刊:
Physics in medicine and biology
影响因子:
3.5
作者:
[Tranel J, Feng FY, James SS, Hope TA]
通讯作者:
Hope TA
DOI:
10.2967/jnumed.121.262821
发表时间:
2022-01
期刊:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子:
--
作者:
[Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohamad O, Pampaloni MH, Scott PJH, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Piert M]
通讯作者:
Piert M
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer
-
批准号:10388424
-
项目类别:
-
资助金额:$11.04万
-
财政年份:2020
-
负责人:Felix Yi-Chung Feng
-
依托单位:
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer
-
批准号:10433829
-
项目类别:
-
资助金额:$62.09万
-
财政年份:2020
-
负责人:Felix Yi-Chung Feng
-
依托单位:
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer
-
批准号:10669118
-
项目类别:
-
资助金额:$65.52万
-
财政年份:2020
-
负责人:Felix Yi-Chung Feng
-
依托单位:
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer
-
批准号:10524143
-
项目类别:
-
资助金额:$5.43万
-
财政年份:2020
-
负责人:Felix Yi-Chung Feng
-
依托单位:
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer
-
批准号:10310721
-
项目类别:
-
资助金额:$7.18万
-
财政年份:2020
-
负责人:Felix Yi-Chung Feng
-
依托单位:
MELT: Modulation of PSMA Expression for Lutetium Therapy
-
批准号:10220901
-
项目类别:
-
资助金额:$65.12万
-
财政年份:2019
-
负责人:Felix Yi-Chung Feng
-
依托单位:
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies
-
批准号:10053722
-
项目类别:
-
资助金额:$53.39万
-
财政年份:2018
-
负责人:Felix Yi-Chung Feng
-
依托单位:
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies
-
批准号:10523108
-
项目类别:
-
资助金额:$65.19万
-
财政年份:2018
-
负责人:Felix Yi-Chung Feng
-
依托单位:
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies
-
批准号:10304164
-
项目类别:
-
资助金额:$59.86万
-
财政年份:2018
-
负责人:Felix Yi-Chung Feng
-
依托单位:
海外基金